Nombre del producto:(2R,5S)-1-Boc-2,5-dimethyl-piperazine

IUPAC Name:tert-butyl (2R,5S)-2,5-dimethylpiperazine-1-carboxylate

CAS:309915-46-6
Fórmula molecular:C11H22N2O2
Pureza:98%
Número de catálogo:CM169834
Peso molecular:214.31

Unidad de embalaje Stock disponible Precio($) Cantidad
CM169834-10g in stock Ȧƻ
CM169834-25g in stock ŴƱƙ
CM169834-100g in stock ƱȁƱ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :309915-46-6
Fórmula molecular:C11H22N2O2
Punto de fusión:-
Código de sonrisas:O=C(N1[C@H](C)CN[C@@H](C)C1)OC(C)(C)C
Densidad:
Número de catálogo:CM169834
Peso molecular:214.31
Punto de ebullición:280°C at 760 mmHg
Nº Mdl:MFCD06797728
Almacenamiento:Store at 2-8°C.

Category Infos

Piperazines
Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

Column Infos

MK-1084
Merck initiates Phase 3 clinical trial of MK-1084, an investigational oral KRAS G12C inhibitor, in combination with KEYTRUDA® (pembrolizumab) for first-line treatment of certain patients with metastatic non-small cell lung cancer. KRAS mutations are one of the most frequently observed mutations in human cancers, making them a crucial target for precision oncology therapy.
MK-1084 is an investigational, oral covalent inhibitor of KRAS G12C, that is found in about 14% of people with non-small cell lung cancer. MK-1084 is currently under Phase 1 evaluation as monotherapy and as combined therapies in patients with KRAS G12C mutant advanced solid tumors.

Related Products